Medical Technology
搜索文档
3 Top Dividend Stocks I Plan to Buy Hand Over Fist in 2026
The Motley Fool· 2025-12-20 18:15
These companies should have no trouble continuing to increase their dividends in 2026.Investing in dividend stocks is a proven way to grow wealth. Over the last 50 years, dividend stocks have delivered more than double the average annual total return compared to non-dividend payers, according to data from Ned Davis Research and Hartford Funds. The highest total returns have come from companies that steadily increase their dividend payments. Brookfield Renewable (BEPC +1.36%)(BEP +0.79%), Realty Income (O 0. ...
Lifeward Appoints Bob Marshall as Chairman of the Board
Globenewswire· 2025-12-19 21:05
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medic ...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine
Globenewswire· 2025-12-19 06:00
Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personali ...
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Globenewswire· 2025-12-18 21:05
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The ...
Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD
Globenewswire· 2025-12-18 21:05
Reinforces Role of AI-Powered Quantitative Coronary Plaque AssessmentMOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), announced the American College of Cardiology (ACC) and the American Heart Association (AHA) published new scientific statements supporting the prognostic value of quantifying coronary plaque and reinforcing the critical role of the coronary computed tomography angiography (CTA) ...
Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026
Businesswire· 2025-12-18 16:00
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Chuck Ravetto, Chief Operating Officer, will be participating at the CJS Securities 26 Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026, which is being held virtually. More information about Novanta is available on the Company's website at www.novanta.com. For additional information, please cont ...
Why Stryker (SYK) is a Top Growth Stock for the Long-Term
ZACKS· 2025-12-18 15:46
Zacks Premium服务与投资工具 - Zacks Premium是一项研究服务,旨在帮助投资者更明智、更自信地进行投资,提供包括Zacks Rank、Zacks Industry Rank每日更新、Zacks 1 Rank List、股票研究报告和高级股票筛选器在内的多种工具 [1] - 该服务还包含Zacks Style Scores的访问权限 [1] Zacks Style Scores详解 - Zacks Style Scores是一套独特的评级指南,根据价值、增长和动量三种投资类型对股票进行评级,作为Zacks Rank的补充指标,帮助投资者选择在未来30天最有可能跑赢市场的证券 [2] - 每只股票根据其价值、增长和动量特征被赋予A、B、C、D或F的评级,评分越高,股票表现跑赢市场的可能性越大 [3] - Style Scores具体分为四个类别:价值评分、增长评分、动量评分和VGM评分 [3] 各类Style Scores评分标准 - 价值评分:考量市盈率(P/E)、市盈率相对盈利增长比率(PEG)、市销率(Price/Sales)、市现率(Price/Cash Flow)等一系列比率,以找出最具吸引力且被低估的股票 [3] - 增长评分:分析预测及历史盈利、销售额和现金流等特征,以寻找能够持续增长的股票 [4] - 动量评分:利用一周价格变动和盈利预测的月度百分比变化等因素,识别建立股票头寸的良好时机 [5] - VGM评分:综合了价值、增长和动量三种评分,基于其加权组合对每只股票进行评级,帮助投资者找到最具吸引力价值、最佳增长预测和最有望形成动量的公司,也是与Zacks Rank配合使用的最佳指标之一 [6] Zacks Rank与Style Scores的协同应用 - Zacks Rank是一个利用盈利预测修正(即公司盈利预期的变化)来帮助投资者构建成功投资组合的专有股票评级模型 [7] - Zacks Rank 1(强力买入)股票自1988年以来实现了无与伦比的+23.81%的平均年回报率,是标普500指数回报率的两倍多 [8] - 在任何给定日期,有超过200家公司被评为强力买入,另有约600家被评为2(买入),总计超过800只顶级评级股票 [8] - 为最大化回报,应选择同时具有Zacks Rank 1或2以及Style Scores为A或B的股票,如果考虑3(持有)评级的股票,也应确保其具有A或B的评分以保障上行潜力 [9] - 即使股票具有A或B的Style Scores,但如果其Zacks Rank为4(卖出)或5(强力卖出),则盈利预测仍在下降,股价下跌的可能性更大 [10] - 投资者持有的具有1或2 Rank以及A或B Scores的股票越多越好 [10] 案例公司:史赛克 - 史赛克公司总部位于密歇根州卡拉马祖,是医疗技术领域的全球领导者,业务组合涵盖骨科、医疗外科和神经技术 [11] - 2024年,该公司约60%的销售额来自医疗外科和神经技术部门,40%来自骨科部门,约四分之三的收入来自美国,国际销售额(约25%)提供了增长机会 [11] - 该公司在Zacks Rank上被评为3(持有),VGM评分为B [12] - 对于增长型投资者而言,该公司可能是一个首选,其增长评分为B,预计当前财年盈利同比增长11.2% [12] - 对于2025财年,过去60天内10位分析师上调了其盈利预测,Zacks共识预期每股收益上调0.06美元至13.56美元,该公司平均盈利意外为+2.9% [12] - 凭借坚实的Zacks Rank以及顶级的增长和VGM Style Scores,史赛克应列入投资者的关注名单 [13]
Baxter International Inc. (BAX): A Bull Case Theory
Yahoo Finance· 2025-12-18 15:40
We came across a bullish thesis on Baxter International Inc. on Value investing subreddit by Mr-Gambini. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.'s share was trading at $19.29 as of December 17th. BAX’s forward P/E was 8.12 according to Yahoo Finance. Copyright: nimon / 123RF Stock Photo Baxter International (BAX) is a quintessential “boring but essential” medtech company operating in oligopolistic markets for IV solutions, infusion pumps, patient monitoring ...
3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
ZACKS· 2025-12-18 15:11
Key Takeaways TMDX, GMED and HIMS saw strong gains driven by innovation and improved financial performance in 2025.GMED, TMDX and HIMS may face pressure in 2026 amid selective spending and valuation resets.GMED rose 3.8%, TMDX 101.4% and HIMS 32.6% over the past year, outpacing the industry's performances.In 2024 and 2025, the MedTech sector has operated against a backdrop of a global economy marked by slowing growth, moderating inflation and elevated geopolitical uncertainty. Worldwide policy shifts, persi ...
What Makes Stryker Corp. (SYK) a High-Quality, Defensive Compounder?
Yahoo Finance· 2025-12-18 14:30
Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the Russell 1000 Value Index, which returned 5.33% for the same period. During the quarter, the portfolio reduced its weight in the IT sector to increase ho ...